

Gatimin-OZ®



Gatimin-oz

Each tablet contains Composition

Gatifloxacin......200 mg
Ornidazole......500 mg Indications

Respiratory tract infections like lung abscess, aspiration pneumonia, empyema and bronchiectasis.

ENT infections like chronic sinusitis, chronic suppurative otitis media, cholesteatoma and mastoiditis.

Dermatological infections like cellulitis, breast and other cutaneous abscesses, gangrene and decubitus ulcers. Orofacial and dental infections.

Surgical wound infections.

Gynaecological infections including

Description

Gatifloxacin, a new type of quinolone antibiotic, has been approved by the U.S. Food and Drug Administration for indications including the treatment of community-acquired respiratory tract infections (RTIs). It was designed with a unique 8-methoxy structure that appears to enhance bactericidal action and decrease the rate of the development of resistance of gram-positive bacteria.

Quinolones rapidly inhibit DNA synthesis by promoting cleavage of bacterial DNA in the DNA-enzyme complexes of DNA gyrase and type IV topoisomerase, resulting in rapid bacterial death. As a general rule, gram-negative bacterial activity correlates with inhibition of DNA gyrase, and gram-positive bacterial activity corresponds with inhibition of DNA type IV topoisomerase.

Quinolones inhibit two specific enzymes, DNA gyrase and DNA topoisomerase IV, which aid in bacterial DNA replication. FACTIVE displays strong binding affinity at both of these target sites, which helps maintain high in vitro potency against resistant S pneumoniae. This dual targeting with FACTIVE is achievable at therapeutic drug levels.

The antimicrobial activity of ornidazole is due to the reduction of the nitro group to a more reactive amine that attacks microbial DNA, brings about loss of helical structure of DNA and subsequent DNA breakage thus inhibiting further synthesis and causing degradation of existing DNA.



Gatimin-OZ®



Gatimin-oz

Quinolones inhibit two specific enzymes, DNA gyrase and DNA topoisomerase IV, which aid in bacterial DNA replication. FACTIVE displays strong binding affinity at both of these target sites, which helps maintain high in vitro potency against resistant S pneumoniae. This dual targeting with FACTIVE is achievable at therapeutic drug levels.

The antimicrobial activity of ornidazole is due to the reduction of the nitro group to a more reactive amine that attacks microbial DNA, brings about loss of helical structure of DNA and subsequent DNA breakage thus inhibiting further synthesis and causing degradation of existing DNA.

Contraindications

Gatifloxacin is contraindicated in persons with a history of hypersensitivity to gatifloxacin or any member of the quinolone class of antimicrobial agents.

Ornidazole is contraindicated in persons with a history of hypersensitivity ornidazole and other imidazoles.

Warnings and precautions

Special precautions are required in case of ataxia, vertigo, mental confusion and patients with neurological diseases. There is need for adjustment of dosage and dosage interval in patients with hepatic impairment. Modification of the usual dosage is not necessary in patients of renal failure however, additional post haemodialysis dose may be required in patients undergoing this procedure.

Dosage

The recommended dosage for Gatimin-OZ tablets is described below. Doses of Gatimin-OZ are administered once every 24 hours.

Presentations

10 tablets

<u>Note</u>: This product information is intended only for residents of the India. Taj Pharmaceuticals Limited, medicines help to treat and prevent a range of conditions—from the most common to the most challenging—for people around the world.

Information for Health Care Professionals

*** Please consult local Prescribing Information for any product before use. This website is an international information resource for healthcare professionals with an interest in disease management. This website is not intended to replace the advice of a qualified healthcare professional. Above brand is a trademark of the Taj group of companies (Taj Pharmaceuticals Limited).